Mary Hamby

Dr. Hamby joined Cognition in 2019 as director of biology to identify pharmacodynamic biomarkers that may be leveraged to guide the company’s clinical trial design and inform in vivo studies in planned neurodegenerative and neuro-ophthalmology studies. Prior to joining Cognition Therapeutics, Dr. Hamby was the head of the neuroinflammation at the Neurodegeneration Consortium at MD Anderson where she led efforts to discover novel therapeutics, advance a portfolio of drug discovery programs and nominated clinical biomarkers of Alzheimer’s disease. Prior to joining the Neurodegeneration Consortium, as a scientist at Lundbeck, Dr. Hamby generated key in vitro and in vivo proof-of-concept data, enabled target identification and validation, and helped guide nomination of the lead candidates for various CNS disorders. She earned a B.S. from the University of Florida and a Ph.D. From the University of Connecticut in biomedical science with a specialization in neuroscience.

Her postdoctoral work at UCLA in the laboratory of Dr. Michael Sofroniew examined the impact of pro-inflammatory factors on the expression of genes and cellular pathways in CNS disease. She has authored 16 papers on the role of inflammation and pro-inflammatory factors in neurodegenerative disease.